Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$79.53 USD
-1.83 (-2.25%)
Updated Jun 10, 2024 04:00 PM ET
Pre-Market: $79.53 0.00 (0.00%) 8:38 AM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 481 - 500 ( 718 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Appears Evomela CRL Should be Non- Event; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Evomela CRL; Buffered Downside for Ligand; Target Tweaked
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Prepping for Sparsentan; Time to Remind on Investment Case
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Expecting Strong 3Q15; Support by Broad Opportunities; Target to $140
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Looking for Another Kyprolis Label Expansion; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Promacta, Evomela and Good Looking Scripts; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotech Names for the Turn and the Long Haul
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Additional Promacta Label Expansion Highlights Growth Path
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2Q15 Results; Strong Commercial and Licensing Momentum; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.